Robert Ofenloch
University Hospital Heidelberg
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Robert Ofenloch.
British Journal of Dermatology | 2016
Thomas L. Diepgen; Robert Ofenloch; Magnus Bruze; Paola Bertuccio; Simone Cazzaniga; P J Coenraads; Peter Elsner; Margarida Gonçalo; Åke Svensson; Luigi Naldi
Population‐based studies about contact allergy are scarce.
Journal of Investigative Dermatology | 2016
Thomas L. Diepgen; Luigi Naldi; Magnus Bruze; Simone Cazzaniga; Marielouise Schuttelaar; Peter Elsner; Margarida Gonçalo; Robert Ofenloch; Åke Svensson
Population-based studies on contact allergy to p-phenylenediamine (PPD) are scarce. A cross-sectional study was performed to assess the prevalence of contact allergy to PPD and its risk factors in the general population of 5 European countries. A total of 10,425 subjects were interviewed, and a random sample (n = 2,739) was patch tested to PPD. Overall, 5,286 individuals (50.9%) reported having used hair colorants at least once in their lifetime (78% female, 20% male), and 35% had used hair colorants during the last 12 months. Hair colorant avoidance because of any skin problem during the lifetime was reported by 6%. Black henna tattoos had been used by 5.5% during their lifetime. The prevalence of PPD contact allergy was 0.8% (95% confidence interval 0.6-1.0%), with no statistically significant association with gender or hair dye use. The prevalence of PPD in black henna tattoo users was 3.2% versus 0.6% in nonusers (P < 0.001). A clinically relevant positive patch test reaction to PPD related to hair coloring products was found in 0.1% (95% confidence interval 0.0-0.2%). A significant association with PPD contact allergy was observed for subjects who had black henna tattoos in their lifetime, with an age- and gender-adjusted odds ratio of 9.33 (95% confidence interval 3.45-25.26, P < 0.001). Black henna tattoos are an important risk factor for PPD contact allergy.
Allergy | 2016
Daniel Heinl; Cecilia A.C. Prinsen; Stefanie Deckert; Joanne R. Chalmers; Aaron M. Drucker; Robert Ofenloch; Rosemary Humphreys; Tracey Sach; Sarah L. Chamlin; Jochen Schmitt; Christian Apfelbacher
BACKGROUND The Harmonising Outcome Measures for Eczema (HOME) initiative has identified quality of life (QoL) as a core outcome domain to be evaluated in every eczema trial. It is unclear which of the existing QoL instruments is most appropriate for this domain. Thus, the aim of this review was to systematically assess the measurement properties of existing measurement instruments developed and/or validated for the measurement of QoL in adult eczema. METHODS We conducted a systematic literature search in PubMed and Embase identifying studies on measurement properties of adult eczema QoL instruments. For all eligible studies, we assessed the adequacy of the measurement properties and the methodological quality with the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) checklist. A best evidence synthesis summarizing findings from different studies was the basis to assign four degrees of recommendation (A-D). RESULTS A total of 15 articles reporting on 17 instruments were included. No instrument fulfilled the criteria for category A. Six instruments were placed in category B, meaning that they have the potential to be recommended depending on the results of further validation studies. Three instruments had poor adequacy in at least one required adequacy criterion and were therefore put in category C. The remaining eight instruments were minimally validated and were thus placed in category D. CONCLUSIONS Currently, no QoL instrument can be recommended for use in adult eczema. The Quality of Life Index for Atopic Dermatitis (QoLIAD) and the Dermatology Life Quality Index (DLQI) are recommended for further validation research.
British Journal of Dermatology | 2017
Daniel Heinl; Cecilia A.C. Prinsen; Tracey Sach; Aaron M. Drucker; Robert Ofenloch; Carsten Flohr; Christian Apfelbacher
Quality of life (QoL) is one of the core outcome domains identified by the Harmonising Outcome Measures for Eczema (HOME) initiative to be assessed in every eczema trial. There is uncertainty about the most appropriate QoL instrument to measure this domain in infants, children and adolescents.
British Journal of Dermatology | 2015
Thomas L. Diepgen; Robert Ofenloch; Magnus Bruze; Simone Cazzaniga; P J Coenraads; Peter Elsner; Margarida Gonçalo; Åke Svensson; Luigi Naldi
Contact allergy to fragrances is assessed mostly in clinical populations of patients. Studies in the general population are scarce and vary in their methodology across countries.
JAMA Dermatology | 2014
Luigi Naldi; Simone Cazzaniga; Margarida Gonçalo; Thomas L. Diepgen; Magnus Bruze; Peter Elsner; Peter Jan Coenraads; Åke Svensson; Paola Bertuccio; Robert Ofenloch
IMPORTANCE Skin disorders are common in the general population, and they may be associated with significant disability. The use of daily skin products may affect the appearance and severity of skin conditions. OBJECTIVES To assess the prevalence of reported itchy rash lasting longer than 3 days among the general population and to evaluate lifetime avoidance of different types of consumer products because of skin problems. DESIGN, SETTING, AND PARTICIPANTS The European Dermato-Epidemiology Network (EDEN) Fragrance Study comprised a large descriptive epidemiological survey of the general population conducted in 6 European regions from August 20, 2008, to October 10, 2011. Participants were a random sample of individuals aged 18 to 74 years, based on electoral precincts. The participants were interviewed using a standardized questionnaire. EXPOSURES Lifetime exposure to products of common use was considered, including toiletry items that remained on the skin or were rinsed off and household and functional items. MAIN OUTCOMES AND MEASURES The 1-month, 1-year, and lifetime age-standardized prevalence rates of itchy rash that lasted longer than 3 days. RESULTS In total, 12 377 individuals (53.9% female; median age, 43 years) were interviewed. The overall prevalences of itchy rash were 19.3% (95% CI, 18.6%-20.0%) during the month preceding the interview, 31.8% (95% CI, 31.0%-32.6%) during the preceding year, and 51.7% (95% CI, 50.8%-52.6%) over a lifetime. In addition, the percentage of individuals who reported avoidance of any product varied from 37.0% for products intended to be left on the skin to 17.7% for household or functional products. CONCLUSIONS AND RELEVANCE Our findings confirmed the magnitude of skin problems among the general population reported in other surveys. Although itchy rash is a nonspecific manifestation, it may be considered in epidemiological surveys to reflect a constellation of skin conditions and to summarize the burden of these conditions on general health.
Contact Dermatitis | 2016
Richard Brans; Christoph Skudlik; Elke Weisshaar; Reginald Scheidt; Robert Ofenloch; Peter Elsner; Britta Wulfhorst; Michael Schönfeld; Swen Malte John; Thomas L. Diepgen
A tertiary individual prevention programme (TIP) is offered to patients with severe occupational skin disease (OSD) in Germany. Previously, it was shown that the burden of OSDs is considerably reduced in patients up to 1 year after the TIP.
Contact Dermatitis | 2015
Robert Ofenloch; Thomas L. Diepgen; Ana Popielnicki; Elke Weisshaar; Sonja Molin; Andrea Bauer; Vera Mahler; Peter Elsner; Jochen Schmitt; Christian J. Apfelbacher
The Occupational Contact Dermatitis Disease Severity Index (ODDI) was designed in Australia to measure severity and functional disability in patients with occupational contact dermatitis (OCD) of the hands. The ODDI was translated into the German language with a linguistic validation process. The psychometric properties of the German version of the ODDI are still unclear.
Systematic Reviews | 2016
Daniel Heinl; Cecilia A.C. Prinsen; Aaron M. Drucker; Robert Ofenloch; Rosemary Humphreys; Tracey Sach; Carsten Flohr; Christian Apfelbacher
BackgroundEczema is a common chronic or chronically relapsing, inflammatory skin disease that exerts a substantial negative impact on quality of life (QoL). The Harmonising Outcome Measures for Eczema (HOME) initiative has used a consensus-based process which identified QoL as one of the four core outcome domains to be assessed in all eczema clinical trials. A number of measurement instruments exist to measure QoL in infants, children, and adolescents with eczema, and there is a great variability in both content and quality of the instruments used. Therefore, the objective of the proposed research is to comprehensively and systematically assess the measurement properties of the existing measurement instruments that were developed and/or validated for the measurement of patient-reported QoL in infants, children, and adolescents with eczema.Methods/designThis study is a systematic review of the measurement properties of patient-reported measures of QoL developed and/or validated for infants, children, and adolescents with eczema. A systematic literature search will be carried out in MEDLINE via PubMed and EMBASE using a selection of relevant search terms. Eligible studies will be primary empirical studies evaluating, describing, or comparing measurement properties of QoL instruments for infants, children, and adolescents with eczema. Two reviewers will independently perform eligibility assessment and data abstraction. Evidence tables will be used to record study characteristics, instrument characteristics, measurement properties, and interpretability. The adequacy of the measurement properties will be assessed using predefined criteria. The COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) checklist will be used to evaluate the methodological quality of included studies. A best evidence synthesis will be undertaken if more than one study has examined a particular measurement property.DiscussionThe proposed systematic review will yield a comprehensive assessment of measurement properties of existing QoL instruments in infants, children, and adolescents with eczema. The results will serve as a basis to recommend a QoL measurement instrument for infants, one for children, and one for adolescents for use in future clinical trials.Systematic review registrationPROSPERO CRD42015023483
British Journal of Dermatology | 2018
Simone Cazzaniga; Christian Apfelbacher; Thomas L. Diepgen; Robert Ofenloch; Elke Weisshaar; Sonja Molin; Andrea Bauer; Vera Mahler; Peter Elsner; Jochen Schmitt; Barbara K. Ballmer-Weber; Philipp Spring; Luigi Naldi; Luca Borradori; Dagmar Simon; Switzerland
Hand eczema has a high incidence and prevalence and has a negative impact on both physical and psychological well‐being, with the risk of persistence as a chronic condition. Epidemiological studies on hand eczema provided mainly descriptive and risk analyses, but pattern analyses of variables associated with hand eczema, in particular chronic hand eczema, have not been explored to date.